Advertisement
News
Advertisement

Everist Genomics Announces Worldwide Availability of OncoDefenderâ„¢-CRC

Mon, 03/28/2011 - 5:35am
Bio-Medicine.Org

ANN ARBOR, Mich., March 28, 2011 /PRNewswire/ -- Everist Genomics today announced the worldwide commercial availability of its OncoDefender-CRC colorectal cancer assay, the first and only molecular prognostic test capable of accurately predicting the risk of recurrence of cancer in patients previously treated with surgical resection of a Stage I/II colon cancer tumor or Stage I rectal cancer tumor.  The OncoDefender-CRC test examines expression levels of a panel of genes extracted from formalin-fixed paraffin-embedded cancer tissue taken at the time of surgery, and uses a proprietary computer-generated decision rule to identify patients who are at risk of recurrence.  Patients identified by OncoDefender-CRC at high-risk of cancer recurrence may benefit from adjuvant therapy or other more aggressive treatment options, as reported at the 2011 American Society of Clinical Oncology (ASCO) meeting. (1)

(Logo: https://photos.prnewswire.com/prnh/20110110/NY26865LOGO)

"We are pleased to deliver a new molecular prognostic test capable of assessing recurrence risk in early stage colorectal cancer patients, including the neglected stage I subset, where the lack of positive predictive prognostics presents a significant unmet need," said Prasad Sunkara, Ph.D., Chief Executive Officer of Everist Genomics.  OncoDefender-CRC was developed through extensive clinical research and assay validation studies involving over 500 patients from around the world.  "OncoDefender-CRC will help physicians make patient management decisions that promptly and reliably direct the most effective treatment to those individual Stage I/II colon cancer and Stage I rectal cancer patients at high risk for tumor recurrence, while minimizing the exposure of low-risk patients to unnecessary, costly, and potentially toxic chemotherapy and/or radiotherapy."

Traditional standards for assessing a patient's risk of cancer recurrence have depended solely on the cancer's a

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading